Glaukos’ Tiny Medical Devices Fuel Expansion for Ophthalmology

7h ago, source: Orange County Business Journal

Microscopic in size, the company’s products Aliso Viejo-based Glaukos, dubbed the iStent, are often used in conjunction with cataract surgery for the reduction of intraocular pressure.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

7d ago, source: Zacks.com on MSN

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

14d ago, source: Zacks.com on MSN

Shares of Glaukos Corporation GKOS scaled a new 52-week high of $97.77 on Apr 5, before closing the session slightly lower at $96.77. Over the past year, this Zacks Rank #3 (Hold) stock has surged 98.

Glaukos Corporation (GKOS)

3d ago, source: Yahoo Finance

ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma ...

Glaukos Announces the Release of its 2023 Sustainability Report

6d ago, source: Stockhouse

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Analyst Ratings For Glaukos

14d ago, source:

Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to ...

Is Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?

11d ago, source:

Glaukos is still trading at a fairly cheap price. According to our valuation, the intrinsic value for the stock is $151.52, but it is currently trading at US$99.71 on the share market, meaning that ...

Glaukos Corp.

26d ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Glaukos corp executive sells over $6 million in company stock

12d ago, source: Investing

Glaukos Corp (NYSE:GKOS) reported that its President & COO, Joseph E. Gilliam, sold a total of $6,008,358 worth of company stock, according to a recent SEC filing. The transactions occurred on ...

Glaukos Corp president & COO sells $38.6k in stock

17d ago, source: Investing

Glaukos Corp (NYSE:GKOS) has recently seen notable insider trading activity from its President and Chief Operating Officer, Joseph E. Gilliam. According to the latest Form 4 filing with the SEC, ...

Glaukos Announces the Release of its 2023 Sustainability Report

6d ago, source: Morningstar

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...